利伐沙班片（拜瑞妥）能不能随便停药？

It is the world's first oral direct factor Xa inhibitor and is also clinically used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome. 

Rivaroxaban tablets (Xarelto) usage and dosage:

1. Rivaroxaban tablets (Xarelto) are used to prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery: the recommended dose is oral rivaroxaban 10 mg, once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery. For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the dose once daily the next day.

2. Rivaroxaban tablets (Xarelto) treat DVT and reduce the risk of acute DVT recurrence and PE: The recommended dose for the initial treatment of acute DVT is 15 mg twice a day for the first three weeks, and then the dosage for maintenance treatment and reducing the risk of DVT recurrence and PE is 20 mg once a day. In the later stage, the current view is that it can also be taken in small doses, namely 10mg, once a day.

3. After carefully evaluating the benefits of treatment and the risk of bleeding, the duration of treatment should be determined based on individual circumstances. Short-term treatment (3 months) should be based on transient risk factors (eg, recent surgery, trauma, immobilization), and long-term treatment should be based on permanent risk factors or idiopathic DVT.

Can Rivaroxaban Tablets (Xarelto) be stopped at will?

It is not recommended to stop the drug (Xarelto) casually to avoid developing drug resistance.

Recommended related hot articles: /newsDetail/81597.html